免疫球蛋白G4相关疾病及其多样的心血管表现
本文为叙述性综述,总结IgG4相关疾病(IgG4-RD)的心血管表现,提出包括主动脉炎、中血管动脉炎、肺血管病、静脉炎、瓣膜病、心包炎、心肌病及ANCA相关血管炎的分类,并回顾影像诊断及药物与手术治疗进展,指出该病易被漏诊且缺乏随机试验证据。
要点
- IgG4-RD心血管受累可表现为主动脉炎、瓣膜病、心包炎等多种类型,易被常见心血管病掩盖。
- 心血管病变常需手术干预如主动脉瘤修复和瓣膜置换,全身糖皮质激素是治疗基石。
- 生物制剂和改善病情药物应用渐广,但缺乏随机试验证据,诊断与管理存在知识缺口。
核心结论
- IgG4-RD的心血管表现多样且可导致严重并发症,若不积极评估容易漏诊。
- 心内科医生应将心血管IgG4-RD纳入鉴别诊断,并了解激素、改善病情药物、生物制剂与手术的整合应用。
研究设计与样本
- 叙述性综述,总结已发表文献中IgG4-RD的心血管表现,为诊断和管理提供依据。
主要发现
- 提出心血管IgG4-RD分类:主动脉炎、中血管动脉炎、肺血管病、静脉炎、瓣膜病、心包炎、心肌病和抗中性粒细胞胞质抗体相关血管炎。
- 心血管病变常需操作和/或手术干预,如主动脉瘤修复和瓣膜置换。
- 临床表现常模仿由更常见病因(如心肌梗死、腹主动脉瘤等)引起的心血管疾病,可能导致诊断不足。
- 全身糖皮质激素是IgG4-RD治疗的主要手段,生物制剂和改善病情药物应用日益广泛。
临床怎么用
- 心内科医生应将心血管IgG4-RD作为鉴别诊断,积极评估以避免漏诊。
- 理解糖皮质激素、改善病情药物和生物制剂的作用及其与手术方法的整合。
局限性
- 诊断、危险因素、发病机制和适当管理存在多个知识缺口。
- 缺乏精心实施的随机试验,包括血管动脉瘤背景下激素的安全性以及改善病情药物和生物制剂在已建立心血管并发症患者中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory disease characterised by multiorgan lymphoplasmacytic infiltration, obliterative phlebitis and storiform fibrosis. It can be associated with cardiovascular pathology. The objective of this narrative review is to summarise the published literature on cardiovascular manifestations of IgG4-RD and to provide a basis for diagnosis and management of the condition by the practising cardiologist.We propose the following categorisations of cardiovascular IgG4-RD: aortitis, medium-vessel arteritis, pulmonary vascular disease, phlebitis, valvulopathy, pericarditis, myocardial disease and antineutrophilic cytoplasmic antibody-associated vasculitis. We also review herein developments in radiological diagnosis and reported medical and surgical therapies. Cardiovascular lesions frequently require procedural and/or surgical interventions, such as aortic aneurysm repair and valve replacement. IgG4-RD of the cardiovascular system results in serious complications that can be missed if not evaluated aggressively. These are likely underdiagnosed, as clinical presentations frequently mimic cardiovascular disease due to more common aetiologies (myocardial infarction, abdominal aortic aneurysm and so on). While systemic corticosteroids are the mainstay of IgG4-RD treatment, biological and disease-modifying agents are becoming more widely used. Cardiologists should be aware of cardiovascular IgG4-RD as a differential diagnosis, and understand the roles of corticosteroids, disease-modifying agents and biologicals, as well as their integration with surgical approaches. There are several knowledge gaps, including diagnosis, risk factors, pathogenesis and appropriate management in Ig4-RD of the cardiovascular system. Areas lacking well-conducted randomized trials include safety of steroids in the setting of vascular aneurysms and the role of disease-modifying drugs and biological agents in patients with established cardiovascular complications of this multifaceted enigmatic disease.
引用
- Shakir A, Wheeler Y, Krishnaswamy G, et al. The enigmatic immunoglobulin G4-related disease and its varied cardiovascular manifestations. Heart. 2021. PMID: 33468575. doi:10.1136/heartjnl-2020-318041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。